Zydelig (idelalisib)

The U.S. Food and Drug Administration (FDA) has approved Zydelig^® (idelalisib) for the treatment of three different B-cell blood cancers:

1. In combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy
2. As monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies
3. As monotherapy for patients with small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies

Eligible patients that are prescribed Zydelig may be able to receive support and assistance through Zydelig AccessConnect™. For more information, please visit Zydelig.com.